Clinical Trial Update: A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation [Phase 1]

View source ↗

Summary

Phase I first-in-human study evaluating GenSci128 in patients with solid tumors harboring a TP53 Y220C mutation; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• GenSci128

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Solid Tumors Harboring a TP53 Y220C Mutation | Phase 1 | Status: RECRUITING